LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

Management of Luminex Corporation (the “Company”) announces that it has reached an agreement with Laboratory Corporation of America Holdings (“LabCorp”) whereby LabCorp has agreed to extend its commitment to the Luminex Cystic Fibrosis (“CF”) product line through December 31, 2019. This indicates that LabCorp would maintain, at a minimum, its current volume of CF testing with Luminex through calendar year 2019.

As the Company will be participating in the Morgan Stanley 2017 Healthcare Conference on September 13, 2017 and the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017, both in New York, New York (“Investor Conferences”), management anticipates interaction with participants at the Investor Conferences and otherwise regarding its commercial relationship with LabCorp. In light of the current extension, and historical inquires about the LabCorp CF test kits and LabCorp’s prior announcement to eventually transfer CF testing to an alternative technology, management deems it appropriate to announce this extension prior to inquiries that could arise at such Investor Conferences. The Company continues to greatly appreciate and enjoy its ongoing relationship with LabCorp.

to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure is deemed to have been furnishedand shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended.

About LUMINEX CORPORATION (NASDAQ:LMNX)

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease.